論文 - 詳細
| RRC ID | 57752 |
|---|---|
| 著者 | Sekido M, Fujita KI, Kubota Y, Ishida H, Takahashi T, Ohkuma R, Tsunoda T, Ishikawa F, Shibanuma M, Sasaki Y. |
| タイトル | Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil. |
| ジャーナル | Cancer Chemother Pharmacol |
| Abstract |
PURPOSE:Several retrospective studies have shown that the antitumor efficacy of capecitabine-containing chemotherapy decreases when co-administered with a proton pump inhibitor (PPI). Although a reduction in capecitabine absorption by PPIs was proposed as the underlying mechanism, the effects of PPIs on capecitabine pharmacokinetics remain unclear. We prospectively examined the effects of rabeprazole on the pharmacokinetics of capecitabine and its metabolites. METHODS:We enrolled patients administered adjuvant capecitabine plus oxaliplatin (CapeOX) for postoperative colorectal cancer (CRC) patients and metastatic CRC patients receiving CapeOX with/without bevacizumab. Patients receiving a PPI before registration were allocated to the rabeprazole group, and the PPI was changed to rabeprazole (20 mg/day) at least 1 week before the initiation of capecitabine treatment. On day 1, oral capecitabine (1000 mg/m2) was administered 1 h after rabeprazole intake. Oxaliplatin (and bevacizumab) administration on day 1 was shifted to day 2 for pharmacokinetic analysis of the first capecitabine dose. Plasma concentrations of capecitabine, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil were analyzed by high-performance liquid chromatography. Effects of rabeprazole on inhibition of cell proliferation by each capecitabine metabolite were examined with colon cancer cells (COLO205 and HCT116). RESULTS:Five and 9 patients enrolled between September 2017 and July 2018 were allocated to rabeprazole and control groups, respectively. No significant effects of rabeprazole on area under the plasma concentration-time curve divided by capecitabine dose for capecitabine and its three metabolites were observed. Rabeprazole did not affect the proliferation inhibition of colon cancer cells by the respective capecitabine metabolites. CONCLUSION:Rabeprazole does not affect capecitabine pharmacokinetics. |
| 巻・号 | 83(6) |
| ページ | 1127-1135 |
| 公開日 | 2019-6-1 |
| DOI | 10.1007/s00280-019-03837-y |
| PII | 10.1007/s00280-019-03837-y |
| PMID | 30972456 |
| MeSH | Aged Antimetabolites, Antineoplastic / administration & dosage* Antimetabolites, Antineoplastic / pharmacokinetics Antineoplastic Combined Chemotherapy Protocols Area Under Curve Capecitabine / administration & dosage* Capecitabine / pharmacokinetics Cell Proliferation / drug effects Chromatography, High Pressure Liquid Colorectal Neoplasms / drug therapy* Deoxycytidine / analogs & derivatives Deoxycytidine / pharmacokinetics Drug Interactions Female Floxuridine / pharmacokinetics Fluorouracil / pharmacokinetics Humans Male Middle Aged Prospective Studies Proton Pump Inhibitors / administration & dosage* Proton Pump Inhibitors / pharmacology Rabeprazole / administration & dosage* Rabeprazole / pharmacology |
| IF | 2.967 |
| 引用数 | 3 |
| リソース情報 | |
| ヒト・動物細胞 | HCT116(RCB2979) |